Delayed neutrophil apoptosis may enhance NET formation in ARDS

Chao Song, Haitao Li, Zhi Mao, Ling Peng, Ben Liu, Fengyu Lin, Yi Li, Minhui Dai, Yanhui Cui, Yuhao Zhao, Duoduo Han, Lingli Chen, Xun Huang, Pinhua PanRespiratory 2022 · DOI

TL;DR

This study reveals a critical link between prolonged neutrophil survival and the exacerbation of acute respiratory distress syndrome (ARDS). By inhibiting neutrophil apoptosis, researchers found a significant reduction in neutrophil extracellular trap (NET) formation, suggesting a promising therapeutic avenue for ARDS.

What Problem Does This Paper Address?

Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition characterized by widespread inflammation, with high mortality rates and limited effective treatments. Neutrophils, a type of white blood cell, are known to play a central role in ARDS pathogenesis. While neutrophils are normally short-lived and undergo programmed cell death (apoptosis) to resolve inflammation, this process appears to be dysregulated in ARDS. Specifically, neutrophils in ARDS patients exhibit delayed apoptosis, leading to their prolonged survival in the lungs. This extended lifespan is hypothesized to contribute to the persistent inflammation seen in ARDS. Furthermore, previous research has indicated that neutrophils can release Neutrophil Extracellular Traps (NETs), which are web-like structures composed of DNA and proteins, and these NETs can also worsen inflammation. The key question this paper addresses is whether the delayed apoptosis of neutrophils in ARDS directly contributes to increased NET formation and, if so, whether targeting neutrophil apoptosis can mitigate ARDS severity.

Methods

The researchers employed a multi-pronged approach combining clinical, animal, and in vitro studies:

  • Clinical Research: They analyzed blood samples from ARDS patients and healthy controls to compare neutrophil apoptosis rates and NET levels (measured as cell-free DNA bound to myeloperoxidase, cf-DNA/MPO). They also investigated correlations between neutrophil apoptosis, NET levels, and disease severity markers like the APACHE II score.
  • Animal Experiments: They used a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI) to mimic ARDS. In this model, they administered AT7519, a cyclin-dependent kinase (CDK) inhibitor known to promote neutrophil apoptosis, to assess its impact on lung injury, neutrophil apoptosis, and NET formation.
  • In Vitro Experiments: They isolated neutrophils from ARDS patients and healthy individuals and cultured them with pro-survival factors (like GM-CSF and LPS) or the CDK inhibitor AT7519. This allowed them to directly study the effects of these factors on neutrophil apoptosis and NET production at the cellular level.

Key techniques included:

  • Flow Cytometry: To quantify neutrophil apoptosis using Annexin V and Propidium Iodide (PI) staining.
  • Western Blotting: To measure the expression levels of key proteins involved in apoptosis (e.g., Mcl-1, cleaved-caspase 3) and signaling pathways (e.g., p-GSK-3β).
  • Immunofluorescence Microscopy: To visualize NET formation (using markers like Cit-H3 and MPO) and cellular structures.
  • PicoGreen Assay: To quantify cf-DNA/MPO levels as a measure of NETs.
  • Hematoxylin-Eosin (HE) Staining: For histopathological assessment of lung tissue damage in the animal model.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Delayed Apoptosis Fuels NETs in ARDS: The study provides strong evidence that neutrophils in ARDS patients have a significantly reduced rate of apoptosis. This prolonged survival appears to directly correlate with increased NET formation.
  • CDK Inhibition as a Therapeutic Strategy: The CDK inhibitor AT7519 effectively reversed the delayed neutrophil apoptosis observed in ARDS, both in vitro and in vivo. This intervention also led to a significant reduction in NET formation.
  • Targeting Apoptosis Alleviates Lung Injury: In the mouse model, promoting neutrophil apoptosis with AT7519 not only reduced NETs but also significantly ameliorated lung injury, as evidenced by reduced edema, inflammation, and overall lung injury scores.
  • A Potential Diagnostic/Prognostic Marker: The study suggests that cf-DNA/MPO levels, a marker of NETs, are elevated in ARDS patients and correlate with disease severity, hinting at their potential as a diagnostic or prognostic tool.
  • GSK-3β Pathway Involvement: The research points to the p-GSK-3β/Mcl-1 pathway as a potential mechanism by which AT7519 promotes neutrophil apoptosis and reduces NET formation.

Key Results

  • Reduced Apoptosis in ARDS: Neutrophils from ARDS patients showed significantly lower apoptosis rates (p=0.001) compared to healthy controls after 24 hours of culture. This effect was more pronounced in moderate-to-severe ARDS cases.
  • Increased NETs in ARDS: Plasma cf-DNA/MPO levels, a marker for NETs, were significantly higher in ARDS patients compared to healthy controls (p<0.0001) and correlated with disease severity.
  • Negative Correlation: Neutrophil apoptosis rate in ARDS patients was negatively correlated with cf-DNA/MPO levels (R=-0.5254, p=0.0120), meaning higher apoptosis was associated with lower NETs.
  • AT7519 Efficacy in Mice: Treatment with AT7519 in LPS-induced ALI mice led to increased neutrophil apoptosis in bronchoalveolar lavage fluid (BALF) (p=0.0002), reduced lung injury scores (p<0.0001), decreased BALF protein (p=0.033), and fewer neutrophils in BALF (p=0.0048) compared to the LPS-only group.
  • AT7519 Reverses Pro-survival Effects: In vitro, AT7519 reversed the anti-apoptotic effects of pro-survival factors like GM-CSF and LPS on ARDS neutrophils, significantly reducing their viability and promoting apoptosis.
  • NET Reduction with AT7519: AT7519 treatment also significantly reduced NET formation markers (Cit-H3 and cf-DNA/MPO) in both in vivo and in vitro settings.

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited Sample Size: The study used a relatively small number of patient samples, particularly for flow cytometry analysis of neutrophils.
  • Peripheral Blood vs. BALF: While some analyses were performed on peripheral blood neutrophils, the inflammatory environment of the lungs is better represented by BALF neutrophils. The study primarily used peripheral blood for some analyses.
  • Mimicking Inflammatory Environment: The in vitro experiments used LPS and GM-CSF to mimic the ARDS environment, which may not fully replicate the complex milieu of human BALF or autologous serum.
  • Mechanism Specificity: While the study implicates the p-GSK-3β/Mcl-1 pathway, it acknowledges that other mechanisms might be involved in the relationship between NET generation and neutrophil apoptosis.
  • Recruitment Not Studied: The effect of AT7519 on neutrophil recruitment to the lungs in the LPS-ALI model was not investigated.

Future work suggested by the authors includes:

  • Expanding the number of clinical samples, especially neutrophils from BALF.
  • Performing RNA-sequencing on collected neutrophils to identify differential pathways.
  • Further investigating the specific molecular mechanisms linking neutrophil apoptosis, NET formation, and macrophage polarization.
  • Exploring the potential of AT7519 as a therapeutic agent for ARDS.

Summary updated

Abstract

Neutrophils with extended lifespan in ARDS usually enhance NET formation, which aggravates inflammation. Enhancing neutrophil apoptosis in ARDS can reduce the formation of NETs, inhibit inflammation, and consequently alleviate ARDS.
BibTeX
@inproceedings{song2022delayed,
  author = {Chao Song and Haitao Li and Zhi Mao and Ling Peng and Ben Liu and Fengyu Lin and Yi Li and Minhui Dai and Yanhui Cui and Yuhao Zhao and Duoduo Han and Lingli Chen and Xun Huang and Pinhua Pan},
  title = {{Delayed neutrophil apoptosis may enhance NET formation in ARDS}},
  booktitle = {Respiratory},
  year = {2022},
  doi = {10.1186/s12931-022-02065-y},
}
Figure